Brief: Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
15/07/2024 21:15
July 15 (Reuters) - Kyverna Therapeutics Inc KYTX.O :
* KYVERNA'S KYV-101 RECEIVES U.S. FDA RMAT DESIGNATION FOR
KYV-101
IN THE TREATMENT OF PATIENTS WITH REFRACTORY STIFF-PERSON
SYNDROME
Source text for Eikon: ID:nPn2TqpZha
Further company coverage: KYTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants